2020年11月5日
· New Results from Phase 1b/2 CARTITUDE-1 Study of BCMA-directed CAR-T Cell Therapy Cilta-cel in Treatment of Patients with RRMM to be Featured in Oral Presentation
SOMERSET, N.J., November 5, 2020—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that new and updated data from CARTITUDE-1 and LEGEND-2 studies, respectively, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.
CARTITUDE-1 data for oral presentation will highlight Phase 1b/2 efficacy and safety results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel). Additional poster presentations for cilta-cel data will include detailed analyses of cytokine release syndrome and health-related quality of life outcomes from CARTITUDE-1. LEGEND-2 data in patients with relapsed or refractory multiple myeloma and extramedullary disease will also be presented as a poster.
“We look forward to sharing new data from the CARTITUDE-1 study in the US and the LEGEND-2 study in China,” said Ying Huang, PhD, interim-CEO and CFO of Legend Biotech. “With our successful clinical efforts and the Company’s collaboration with Janssen, we are uniquely positioned to deliver a novel therapy to patients with multiple myeloma.”
On Saturday, December 5th,during the Myeloma session entitled: Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma, the Phase 1b/2 clinical efficacy and safety data for ciltacel from the CARTITUDE-1 study will be presented.
Following are details of the five abstracts that have been accepted for presentation at the 62nd ASH Annual Meeting & Exposition. For additional information visit: https://www.hematology.org/meetings/annual-meeting/schedule-and-program.
欧盟委员会批准 CARVYKTI®用于复发和难治性多发性骨髓瘤患者的二线..
2024年4月23日
传奇生物CARVYKTI®成为首个且唯一获FDA批准用于多发性骨髓瘤二线治..
2024年4月5日
传奇生物发布首份环境、社会和管治(ESG)报告
2024年3月19日
CARVYKTI®获得美国FDA肿瘤药物咨询委员会用于复发或难治性多发性骨..
2024年3月16日
传奇生物公布2023年全年及第四季度业绩及近期亮点
2024年3月11日
传奇生物获得CHMP对CARVYKTI®用于前线治疗的积极意见
2024年2月23日